Plus   Neg

Stock Alert: AnPac Bio-Medical Gains On Test Volume, Optimistic Revenue Outlook

Shares of biotechnology company AnPac Bio-Medical Science Co., Ltd. (ANPC) are surging more than 90% Wednesday morning after the company reported strong demand for its cancer screening tests and set a record in paid test volume in the third quarter.

For FY20, the company sees revenue growth of 100% to $3 million to $3.3 million. Average selling price (ASP) of its cancer screening test in 2020 is expected to increase year-over-year contributing to a higher revenue growth forecast.

The Company plans to release its full year results in early March 2021.

ANPC is currently trading at $6.77. It has traded in the range of $3.15- $12.18 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Editors Pick
Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow. Pfizer Inc. (PFE) and OPKO Health Inc. (OPK) announced Friday that the European Medicines Agency or EMA has validated for review the Marketing Authorization Application for somatrogon. Pfizer expects a decision from the European Commission in 2022. The company said somatrogon is a long-acting recombinant... German telecom giant Deutsche Telekom AG reported Friday strong growth in fourth-quarter profit mainly driven by T-Mobile US results following the takeover of the competitor Sprint. Looking ahead for fiscal 2021, the company projects higher adjusted EBITDA AL, a key earnings metric.
Follow RTT